By contrast, anti-PD-L1 mAbs displayed significantly enhanced anti-tumour activity when activating FcγR engagement was optimized, effect correlated with the elimination of monocytes and modulation of myeloid cells within the TME. The gene discussed is FCGR2A; the disease is neoplasm.